| Revenue growth | 29% YoY in FY26 |
|---|---|
| Margins | EBITDA margin expanded 508 bps YoY to 30.1% |
| Order book | 155 programs in pipeline; 45 active molecules |
| Demand visibility | Strong; aligned with global pharma outsourcing trends |
| Management confidence | High; confident in 28-30% EBITDA margin sustainability |
Growth
FY26 Revenue reached ₹2,192 Cr (up 29%); EBITDA rose to ₹661 Cr (up 56%); PAT surged 109% to ₹355 Cr.
Outlook
FY27 Capex of ₹1,100-1,300 Cr. Targeted 15-20% revenue CAGR and 28-30% EBITDA margins over 2-3 years.
Risks
Geopolitical tensions in Middle East impacting logistics costs; evolving global tariff environments remain a monitoring area.
Earnings Call filed with BSE, NSE: SAILIFE. Summary written with AI assistance from the document.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,592.20
- Market cap
- ₹33,821 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 93.5×Sector 50.4×
- Promoter holding
- 34.53%-0.08% QoQ
- FII holding
- 19.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Employee Stock Options
Sai Life Sciences Limited has announced the allotment of equity shares under its ESOP scheme. This allotment increases the company's paid-up share capital.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 24,000 shares upon exercise of ESOP 2008 options at ₹188.90 per share. This issuance increases the company's paid-up equity share capital.
- Value
- ₹0.45 Cr
Sai Life Science Annual General Meeting
Sai Life Sciences summarised proceedings of its 27th AGM held 17 Sep 2026. Shareholders adopted FY25-26 financials and re-appointed MD Krishnamraju Kanumuri.
Sai Life Science Investor Presentation: Key Takeaways
Sai Life Sciences delivered strong Q1FY27 performance with revenue of ₹554 Cr, up 12% YoY, and PAT of ₹73 Cr, up 22% YoY, driven by growth in CRO and CDMO segments.
- Call
- Guides 20% growth
Sai Life Science Q1 FY27 Results: Net Profit ₹73.3 Cr, Up 21.2% YoY
Sai Life Science Ltd reported revenue from operations of ₹554.3 Cr (+11.7% YoY) and net profit of ₹73.3 Cr (+21.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹73.3 Cr · +21.2% YoY
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences reported robust FY26 performance with 29% revenue growth and 109% PAT growth, driven by deepening engagement with 19 of top 25 global pharma companies.